ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 219 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2023. The put-call ratio across all filers is 0.74 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $127,378 | -83.5% | 3,573 | -78.7% | 0.00% | -84.6% |
| Q2 2023 | $773,554 | +585925.8% | 16,769 | +408.6% | 0.03% | +550.0% |
| Q1 2023 | $132 | -71.2% | 3,297 | -66.7% | 0.00% | -78.9% |
| Q4 2022 | $459 | -99.8% | 9,911 | +41.5% | 0.02% | +280.0% |
| Q3 2022 | $290,000 | -8.5% | 7,005 | +32.1% | 0.01% | -28.6% |
| Q2 2022 | $317,000 | +21.9% | 5,302 | +48.6% | 0.01% | +250.0% |
| Q1 2022 | $260,000 | +20.4% | 3,569 | +38.6% | 0.00% | -50.0% |
| Q4 2021 | $216,000 | -31.9% | 2,575 | -26.9% | 0.00% | -50.0% |
| Q3 2021 | $317,000 | -72.7% | 3,521 | -71.1% | 0.01% | -73.3% |
| Q2 2021 | $1,162,000 | +133.8% | 12,190 | +179.6% | 0.03% | +275.0% |
| Q1 2021 | $497,000 | +13.7% | 4,360 | +38.0% | 0.01% | -38.5% |
| Q4 2020 | $437,000 | +5.6% | 3,159 | -37.3% | 0.01% | +160.0% |
| Q3 2020 | $414,000 | -23.8% | 5,040 | -27.4% | 0.01% | -77.3% |
| Q2 2020 | $543,000 | +1710.0% | 6,940 | +883.0% | 0.02% | +1000.0% |
| Q4 2019 | $30,000 | +2900.0% | 706 | +1976.5% | 0.00% | – |
| Q3 2019 | $1,000 | -85.7% | 34 | -69.1% | 0.00% | – |
| Q2 2019 | $7,000 | -86.0% | 110 | -83.2% | 0.00% | -100.0% |
| Q3 2018 | $50,000 | +6.4% | 655 | -35.2% | 0.00% | -33.3% |
| Q4 2017 | $47,000 | -66.2% | 1,011 | -61.3% | 0.01% | -45.5% |
| Q3 2017 | $139,000 | – | 2,611 | +52120.0% | 0.01% | – |
| Q2 2017 | $0 | -100.0% | 5 | -98.9% | 0.00% | -100.0% |
| Q4 2016 | $33,000 | +175.0% | 465 | +181.8% | 0.00% | +300.0% |
| Q3 2016 | $12,000 | -7.7% | 165 | -38.7% | 0.00% | 0.0% |
| Q2 2016 | $13,000 | -63.9% | 269 | -53.1% | 0.00% | -80.0% |
| Q1 2016 | $36,000 | -34.5% | 573 | +17.9% | 0.01% | -44.4% |
| Q4 2015 | $55,000 | +1000.0% | 486 | +872.0% | 0.01% | – |
| Q2 2015 | $5,000 | -28.6% | 50 | -53.7% | 0.00% | -100.0% |
| Q1 2015 | $7,000 | +250.0% | 108 | +300.0% | 0.00% | – |
| Q3 2014 | $2,000 | -86.7% | 27 | -91.4% | 0.00% | -100.0% |
| Q1 2014 | $15,000 | – | 314 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
| RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
| First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
| CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
| Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
| Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
| SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |